New Findings Reported from Ottawa Hospital Research Institute Describe Advances in Multiple Myeloma (Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort...).

A recent study conducted at the Ottawa Hospital Research Institute in Canada examined the treatment patterns, outcomes, healthcare utilization, and quality of life of patients with triple class exposed (TCE) multiple myeloma (MM). TCE MM refers to patients who have been treated with an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. The study found that patients with TCE MM continue to have poor outcomes, and newer immunotherapies are often inaccessible outside of clinical trials in publicly funded healthcare systems. The research highlights the urgent need for novel therapies and suggests that future studies should assess whether outcomes and quality of life improve as newer immunotherapies become more accessible. [Extracted from the article]